Melanoma, KIT-mutated

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search

Page editor Section editor
Ryan Nguyen, DO
University of Illinois at Chicago
Chicago, IL, USA

LinkedIn
Elizabeth Buchbinder, MD
Dana-Farber Cancer Institute
Boston, MA, USA

LinkedIn

Note: these are regimens tested in biomarker-specific populations, please see the main melanoma page for other regimens.

Last updated on 2024-07-23:
2 regimens on this page
3 variants on this page


Guidelines

Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.

NCCN


Advanced or metastatic disease, TKI-naive

Imatinib monotherapy

Regimen variant #1, pre-planned escalation

Study Dates of enrollment Evidence
Hodi et al. 2013 (BUS255) 2006-2011 Phase 2

Note: upon progression, the dose of imatinib was escalated; see below.

Biomarker eligibility criteria

  • Gene: KIT
  • Alteration: amplification and mutation
  • Acceptable methods of measurement: PCR or HPLC

Targeted therapy

Continued indefinitely (see note)


Regimen variant #2

Study Dates of enrollment Evidence
Carvajal et al. 2011 (MSKCC 07-014) 2007-2010 Phase 2

Patients had melanomas arising from mucosal, acral, and chronically sun-damaged skin with KIT mutations or amplifications.

Biomarker eligibility criteria

  • Gene: KIT
  • Alteration: amplification or mutation

Targeted therapy

Continued indefinitely

References

  1. MSKCC 07-014: Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, Panageas KS, Busam KJ, Chmielowski B, Lutzky J, Pavlick AC, Fusco A, Cane L, Takebe N, Vemula S, Bouvier N, Bastian BC, Schwartz GK. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011 Jun 8;305(22):2327-34. link to original article dosing details in abstract have been reviewed by our editors link to PMC article PubMed NCT00470470


Advanced or metastatic disease, TKI-exposed

Imatinib monotherapy

Regimen variant #1, pre-planned escalation

Study Dates of enrollment Evidence
Hodi et al. 2013 (BUS255) 2006-2011 Phase 2

Biomarker eligibility criteria

  • Gene: KIT
  • Alteration: amplification and mutation
  • Acceptable methods of measurement: PCR or HPLC

Prior treatment criteria

Targeted therapy

Continued indefinitely

References

  1. BUS255: Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, Friedlander P, Gonzalez R, Weber JS, Gajewski TF, O'Day SJ, Kim KB, Lawrence D, Flaherty KT, Luke JJ, Collichio FA, Ernstoff MS, Heinrich MC, Beadling C, Zukotynski KA, Yap JT, Van den Abbeele AD, Demetri GD, Fisher DE. Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin. J Clin Oncol. 2013 Sep 10;31(26):3182-90. Epub 2013 Jun 17. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT00424515